HomeCompareEMLAF vs ABBV

EMLAF vs ABBV: Dividend Comparison 2026

EMLAF yields 1.71% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EMLAF wins by $330.9K in total portfolio value· pulled ahead in Year 7
10 years
EMLAF
EMLAF
● Live price
1.71%
Share price
$36.30
Annual div
$0.62
5Y div CAGR
68.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$433.3K
Annual income
$265,411.90
Full EMLAF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — EMLAF vs ABBV

📍 EMLAF pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEMLAFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EMLAF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EMLAF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EMLAF
Annual income on $10K today (after 15% tax)
$145.00/yr
After 10yr DRIP, annual income (after tax)
$225,600.12/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, EMLAF beats the other by $204,544.11/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EMLAF + ABBV for your $10,000?

EMLAF: 50%ABBV: 50%
100% ABBV50/50100% EMLAF
Portfolio after 10yr
$267.8K
Annual income
$145,091.83/yr
Blended yield
54.18%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

EMLAF
Analyst Ratings
1
Buy
Consensus: Buy
Price Target
$41.00
+12.9% upside vs current
Range: $41.00 — $41.00
Altman Z
2.7
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EMLAF buys
0
ABBV buys
0
No recent congressional trades found for EMLAF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEMLAFABBV
Forward yield1.71%3.06%
Annual dividend / share$0.62$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR68.3%40.6%
Portfolio after 10y$433.3K$102.3K
Annual income after 10y$265,411.90$24,771.77
Total dividends collected$396.4K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy
Analyst price target$41.00$256.15

Year-by-year: EMLAF vs ABBV ($10,000, DRIP)

YearEMLAF PortfolioEMLAF Income/yrABBV PortfolioABBV Income/yrGap
1$10,987$287.09$11,550$430.00$563.00ABBV
2$12,252$496.14$13,472$627.96$1.2KABBV
3$13,980$870.25$15,906$926.08$1.9KABBV
4$16,521$1,561.85$19,071$1,382.55$2.5KABBV
5$20,580$2,903.04$23,302$2,095.81$2.7KABBV
6$27,709$5,688.18$29,150$3,237.93$1.4KABBV
7← crossover$41,695$12,046.06$37,536$5,121.41+$4.2KEMLAF
8$73,124$28,510.54$50,079$8,338.38+$23.0KEMLAF
9$156,890$78,647.36$69,753$14,065.80+$87.1KEMLAF
10$433,284$265,411.90$102,337$24,771.77+$330.9KEMLAF

EMLAF vs ABBV: Complete Analysis 2026

EMLAFStock

Empire Company Limited, together with its subsidiaries, engages in the food retail and related real estate businesses in Canada. It operates through two segments, Food Retailing, and Investments and Other Operations. The company owns, affiliates, and franchises approximately 1,600 retail stores under various retail banners, including Sobeys, Safeway, IGA, Foodland, FreshCo, Thrifty Foods, Farm Boy, Longo's, and Lawtons Drugs; and approximately 350 retail fuel locations, as well as operates grocery e-commerce stores under the banners, such as Voilà, Grocery Gateway, IGA.net, and ThriftyFoods.com. It also owns interest in the Crombie Real Estate Investment Trust, an open-ended real estate investment trust to own, operate, and develop a portfolio of grocery and pharmacy-anchored shopping centers, freestanding stores, and mixed-use developments; and various equity accounted interests in Genstar partnerships that develop residential real estate properties in Ontario, Western Canada, and the United States. The company was founded in 1907 and is headquartered in Stellarton, Canada.

Full EMLAF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this EMLAF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EMLAF vs SCHDEMLAF vs JEPIEMLAF vs OEMLAF vs KOEMLAF vs MAINEMLAF vs JNJEMLAF vs MRKEMLAF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.